In pregnancy, it may be difficult to differentiate the syndrome of hemolysis, elevated liver enzymes, and low platelets from thrombotic thrombocytopenia purpura. Severely depressed (<5%) or absence of a disintegrin and metalloproteinase with thrombospondin motifs-13 activity levels are associated with thrombotic thrombocytopenia purpura and mildly decreased levels are associated with other disease processes, including preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. We present a case of a patient that presented at 20 weeks gestation with elevated liver enzymes and thrombocytopenia. The diagnosis was unclear at the time of presentation. She underwent induction of labor, and during the postpartum course, she was eventually diagnosed with thrombotic thrombocytopenia purpura; however, her activity level of a disintegrin and metalloproteinase with thrombospondin motifs-13 was only moderately depressed at 15% (normal pregnancy value 41%-105%).
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Case Presentation
A 26-year-old gravid 2 para 1 had a history of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) diagnosed at 22 weeks in her first pregnancy. After presenting with epigastric pain, proteinuria, and elevated blood pressures, she underwent termination of pregnancy. Following delivery, the patient had persistent thrombocytopenia and hemolytic anemia and was subsequently diagnosed with thrombotic thrombocytopenia purpura (TTP). She recovered after 3 courses of plasma exchange therapy.
After 8 years, she presented with symptoms similar to those of her first pregnancy at 20 weeks 3 days gestation. She had hypertension (170 mm Hg systolic and 100 mm Hg diastolic) and 3þ proteinuria. Initially, her hemoglobin was 9.0 g/dL, platelets 43 000/cu mm, serum creatinine 1.0 mg/dL, serum aspartate aminotransferase (AST) 71 mIU/mL, serum alanine aminotransferase (ALT) 88 mIU/mL, and lactate dehydrogenase (LDH) 606 mIU/mL. The patient's coagulation profile was normal with a partial thromboplastin time (PTT) 28.0 seconds, prothrombin time (PT) 12.7 seconds, and International Normalized Ratio (INR) 1.07. The patient was diagnosed with suspected HELLP syndrome and admitted for induction of labor.
During the induction, she required intravenous hydralazine for blood pressure control. Repeat studies 6 hours later revealed that her platelets had declined (23 000/cu mm) and her transaminases and LDH had risen (AST 290 mIU/mL, ALT 258 mIU/mL, LDH 683 mIU/mL). She was transfused platelets. The remainder of her laboratory studies was stable.
The patient delivered a nonviable 230-g infant, 15 hours following admission. Her blood pressures normalized. However, a repeat complete blood count (CBC) 12 hours after delivery revealed a hemoglobin of 6.4 g/dL and platelets of 23 000/cu mm. She was transfused 2 units of packed red blood cells and another 6-unit pack of platelets, to which the response was 8.3 g/dL and 84 000/cu mm. On postpartum day 1, the patient continued to be normotensive, and her epigastric pain resolved. She demonstrated good urine output, and her laboratory values were stable. However, on postpartum day 2, the patient's platelets declined again to 34 000/cu mm. Haptoglobin was <6 mg/dL and rare schistocytes were noted on peripheral smear. A hematology consultation was obtained and plasmapheresis was considered but withheld at that time. The decision was made to continue observation and repeat platelet transfusion resulting in a platelet count of 84 000/cu mm.
Over the next several days, the patient's vital signs were stable and she remained asymptomatic. However, her platelets continued to decline, and on postpartum day 5, the patient's platelets were 35 000/cu mm, hemoglobin 7.7 mg/dL, haptoglobin less than 6 mg/dL, LDH 554 mg/dL, and schistocytes were again noted on peripheral smear. A diagnosis of TTP was given, and the patient underwent plasmapheresis. The activity level of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-13 returned decreased at 15% of normal and was not conclusive for TTP. ADAMTS-13 inhibitor level was also measured and returned at 4 inhibitor units. ADAMTS-13 activity level was measured by a fluorescence resonance energy transfer assay on plasma anticoagulated with citrate.
The patient received daily plasmapheresis for 4 days and was discharged on postpartum day 10 in a good condition. The majority of her laboratory values normalized; her serum creatinine remained at 1.0 mg/dL. Four months after her delivery, a repeat ADAMTS-13 activity level returned as 12% of normal. However, her blood pressure, renal function, and the remainder of her laboratory studies all returned to normal. She will be followed by hematology because of the decreased ADAMTS-13 level and has been counseled regarding an increased risk of developing TTP in future pregnancies or during significant illnesses.
Discussion
TTP is a rare, severe hematologic disorder and is difficult to distinguish from HELLP syndrome, and both rarely present in the second trimester of pregnancy. TTP is a thrombotic microangiopathy that is characterized by systemic aggregation of platelets mediated by large multimers of von Willebrand factor with notably minimal or absent fibrin. ADAMTS-13 is an enzyme that cleaves large multimers of von Willebrand factor on the surface of endothelial cells. Severely depressed (less than 5% of normal activity) ADAMTS-13 activity levels are characteristic of TTP exacerbations. 1 Accurate and rapid diagnosis is necessary to permit the initiation of plasma exchange therapy and significantly reduce mortality associated with TTP. Severely depressed (<5%) or absent levels of ADAMTS-13 activity are associated with TTP, and moderately depressed ADAMTS-13 levels may be found in other disease processes such as preeclampsia and HELLP syndrome. 1, 2 Distinguishing TTP from HELLP syndrome is a diagnostic challenge in the pregnant patient. Hemolysis, severe thrombocytopenia, elevated blood pressures, compromised renal function, mildly elevated liver enzymes, and an elevated LDH are all characteristics of both diseases and were present in both pregnancies of this patient. TTP is significantly less common in pregnancy in comparison to HELLP syndrome. However, 10% to 20% of TTP cases may be fatal, unlike HELLP syndrome, which is rarely lethal. 3 Our patient's initial symptoms of proteinuria, hypertension, and epigastric pain seemed more characteristic of preeclampsia and HELLP syndrome than of TTP. Additionally, the rapid improvement of the patient's blood pressures and epigastric pain following delivery was consistent with HELLP syndrome. However, the patient's persistent thrombocytopenia, unimproved LDH, and worsening of hemolytic anemia several days postdelivery suggest that the patient in reality had TTP or had concomitant HELLP syndrome and TTP. The recurrence of her symptoms in 2 pregnancies is also more consistent with TTP, which is known to have a high recurrence risk 4 whereas HELLP syndrome less frequently recurs. 5 It has been proposed that in cases such as this, an ADAMTS-13 activity level may be useful in distinguishing between the two disease processes. 2, 6 An ADAMTS-13 activity level of 12% to 43% is characteristic of HELLP syndrome, whereas a level of less than 5% is characteristic of TTP. 2 We anticipated that an absent or severely depressed ADAMTS-13 level would direct the diagnosis to TTP in our case and substantiate use of plasmapheresis. 2 This patient's ADAMTS-13 activity level was 15%, which is not pathognomonic for TTP. Although ADAMTS-13 levels can be useful at the extremes, a level greater than 5% to 10% cannot exclude the possibility of TTP as evidenced by this case. Because of the potentially fatal nature of TTP, institution of treatment for this disorder in pregnancy is warranted when the clinical scenario strongly supports the diagnosis, regardless of the ADAMTS-13 activity level. It should be emphasized, however, that there are no reports of an undetectable ADAMTS-13 level in HELLP syndrome. Further limitations exist in the widespread use of ADAMTS-13 activity levels as the test is not performed in most laboratories. The overlap in clinical manifestations and ADAMTS-13 levels in preeclampsia, HELLP syndrome, and TTP emphasizes that each of these conditions represent part of a spectrum of thrombotic microangiopathy in pregnancy.
ADAMTS-13 activity levels are noted to be normally decreased in pregnancy to 71% of normal (41%-105%). This is proposed by some to be the possible reason that TTP is more frequently encountered in pregnancy. 7 In HELLP syndrome, ADAMTS activity levels are even lower at 31% (12%-43%). 2 This raises the possibility that the development of HELLP syndrome could further predispose certain subgroups to developing TTP. Our patient had suppressed ADAMTS-13 activity many months following delivery suggesting that she manifested a baseline mild deficiency which may have predisposed her, possibly along with the development of HELLP, to the onset of TTP during pregnancy. ADAMTS-13 level determinations should be evaluated 4 to 6 months following delivery in all patients with suspected TTP to help define the risk of recurrence. Additionally, further studies of ADAMTS-13 level in pregnant patients with microvascular thrombotic disease is warranted.
